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Human CMV is a β herpes virus that estab-
lishes lifelong infection. Endothelial, renal epi-
thelial, and pulmonary tissue as well as myeloid 
cells all contain latent CMV. Seroprevalence 
increases with age and reaches 30–70% in de-
veloped countries (1). Although serious disease 
can occur, it is rare. In most immunocompetent 
individuals, infection is asymptomatic (2).
The human immune system dedicates tre-
mendous resources to the control of CMV. In 
CMV-seropositive healthy subjects >60 yr of 
age, the total number of CD8+ T cells is twice 
that in age-matched healthy CMV-seronega-
tive subjects (3). The frequency of CD8+ T 
cells specifi  c for individual CMV-derived pep-
tide epitopes is often >1% of the total periph-
eral CD8+ T cell pool (4). CMV-specifi  c 
CD4+ T cells are also frequent. It has been esti-
mated that in 11% of healthy CMV-seropositive 
individuals, between 10 and 40% of the total 
peripheral CD4+ T cell pool is directed against 
CMV epitopes (5). Similar results have been 
reported in HIV-infected patients without ap-
parent CMV disease (6). An exhaustive analysis 
of all 213 human CMV open reading frames 
found that a median of 10% of the total periph-
eral blood memory CD4+ T cells pooled from 
healthy CMV-seropositive individuals was di-
rected against CMV epitopes (7). From these 
data, the frequency of CMV-specifi  c CD4+ T 
cells appears to be much greater than required 
to ensure the production of antibodies and 
functional CD8+ T cells.
The occurrence of CMV disease during 
immunosuppressive treatments and AIDS dem-
onstrates the importance of cellular immunity 
in the control of CMV infection. It is clear 
from many studies that CD8+ T cells play a 
role in the control of viral replication and may 
require CD4+ T cell help to achieve eff  ective 
viral control (8–14). However, there is also 
Acquisition of direct antiviral eff  ector 
functions by CMV-specifi  c CD4+ 
T lymphocytes with cellular maturation
Joseph P. Casazza,1 Michael R. Betts,1,4 David A. Price,2 
Melissa L. Precopio,1 Laura E. Ruff  ,2 Jason M. Brenchley,2 Brenna J. Hill,2 
Mario Roederer,3 Daniel C. Douek,2 and Richard A. Koup1
1Immunology Laboratory, 2Human Immunology Section, and 3Immunotechnology Section, Vaccine Research Center, 
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892
4Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104
The role of CD4+ T cells in the control of persistent viral infections beyond the provision of 
cognate help remains unclear. We used polychromatic fl  ow cytometry to evaluate the 
production of the cytokines interferon (IFN)-𝗄, tumor necrosis factor (TNF)-𝗂, and inter-
leukin (IL)-2, the chemokine macrophage infl  ammatory protein (MIP)-1𝗃, and surface 
mobilization of the degranulation marker CD107a by CD4+ T cells in response to stimula-
tion with cytomegalovirus (CMV)-specifi  c major histocompatibility complex class II peptide 
epitopes. Surface expression of CD45RO, CD27, and CD57 on responding cells was used to 
classify CD4+ T cell maturation. The functional profi  le of virus-specifi  c CD4+ T cells in 
chronic CMV infection was unique compared with that observed in other viral infections. 
Salient features of this profi  le were: (a) the simultaneous production of MIP-1𝗃, TNF-𝗂, 
and IFN-𝗄 in the absence of IL-2; and (b) direct cytolytic activity associated with surface 
mobilization of CD107a and intracellular expression of perforin and granzymes. This poly-
functional profi  le was associated with a terminally differentiated phenotype that was not 
characterized by a distinct clonotypic composition. Thus, mature CMV-specifi  c CD4+ T cells 
exhibit distinct functional properties reminiscent of antiviral CD8+ T lymphocytes.
CORRESPONDENCE
Richard A. Koup: 
rkoup@mail.nih.gov
Abbreviations used: B-LCL, 
B lymphoblastoid cell; 
CMTMR, chloromethyl-
  benzoyl-aminotetramethyl-
rhodamine; MIP, macrophage 
infl  ammatory protein.
The online version of this article contains supplemental material.2866  CD4+ T CELL FUNCTION IN CHRONIC CMV INFECTION | Casazza et al.
increasing evidence that CD4+ T cells may also play a direct 
role in the control of CMV infection. In mice, salivary tissue 
is exempt from CD8+ T cell control of infection, and CMV-
specifi  c CD4+ T cells are required for the clearance of CMV 
from that tissue (15). In humans, reports have shown a corre-
lation between the presence of CMV-specifi  c CD4+ T cells 
and control of disease. Gamadia et al. (16) showed that CMV-
specifi  c CD4+ T cells are essential for protection against dis-
ease in primary infection, even in the presence of functional 
CMV-specifi  c CD8+ T cells. Tu et al. (17) detected lower 
levels of CMV-specifi  c CD4+ T cells after primary infection 
in children with persistent shedding of CMV compared with 
children who did not shed virus; this diff  erence was observed 
even when the levels of CMV-specifi  c CD8+ T cells were 
comparable to those present in seropositive children and 
adults who did not shed virus. However, the mechanism 
through which such CD4+ T cells exert their antiviral eff  ect 
remains unclear.
Cytotoxic CD4+ T cells can be generated in vitro (18–
24); however, most viruses infect a broad range of target cells 
in vivo that do not express MHC class II and therefore can-
not be targeted by CD4+ T cells. Nevertheless, several au-
thors have suggested recently that CD4+ T cells may have a 
direct eff  ect on the control of viral infection in vivo. Suni 
et al. (25) reported a CD4+ CD8dim subset of T cells that can 
lyse whole CMV antigen-loaded EBV-transformed B lym-
phoblastoid cells (B-LCLs) ex vivo. Appay et al. (26) reported 
the presence of increased numbers of perforin-containing 
CD4+ T cells in HIV-infected individuals and showed that 
these cells can kill. Zaunders et al. (27) described Gag-specifi  c 
CD4+ T cells in an HIV-infected long-term nonprogressor 
that express both granzymes A and B, as well as exhibited 
specifi  c cytotoxicity after a brief time in culture. van Leeuwen 
et al. (28) have reported that CMV-specifi  c ex vivo killing by 
CD4+ T cells in PBMCs isolated from a chronically infected 
individual is associated with a CD28− phenotype.
We hypothesized that CD4+ T cells found during chronic 
subclinical CMV infection may express a specifi  c eff  ector 
phenotype. To determine if CMV-specifi  c CD4+ T cells had 
functional characteristics consistent with antiviral eff  ector 
cells, we conducted a detailed characterization of CMV-specifi  c 
CD4+ T cell function in human CMV infection using poly-
chromatic fl  ow cytometry. Specifi  cally, within each MHC 
II–restricted antigen-specifi  c response, we measured the pro-
duction of IFN-γ and TNF-α, two cytokines often used to 
quantify CMV-specifi  c CD4+ T cells (29); IL-2, a cytokine 
associated with helper function (30); macrophage infl  amma-
tory protein (MIP)-1β, a proinfl  ammatory chemokine (31); 
and surface mobilization of CD107a, a marker of degranula-
tion associated with cytolytic function (32). In conjunction, 
Figure 1.  Polyfunctional CMV-specifi  c CD4+ T cell responses. 
(A) Representative plots from subject 7 showing functional profi  les in re-
sponse to cognate antigen (top) and background responses in the absence 
of cognate antigen (bottom). (B) Total frequency of individual peptide-specifi  c 
CD4+ T cell functions. The frequencies of surface mobilization of CD107a and 
production of IFN-γ, IL-2, MIP-1β, and TNF-α are shown for subject 1 (○), 
subject 2 (◇), subject 3 (■),  subject  4  with  peptide  P P W Q A G I L A R N L V P M V   (×), 
subject  4  with  peptide  I I K P G K I S H I M L D V A   (+), subject 5 (◆), subject 6 (□), 
and subject 7 (●) in the total CD4+ population using box plots with the 
data for each individual superimposed. The line in the middle of the box 
represents the median, the top box represents the second quartile, and the 
box below represents the third quartile. (C) Frequency of normalized func-
tional species in subjects shown in B. The mean percentage of the total 
CD4+ response for each of 31 functional species is shown ± SD.JEM VOL. 203, December 25, 2006  2867
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we classifi  ed CMV-specifi  c CD4+ T cell responses based on 
the surface expression of CD45RO, a marker of memory T 
cells, CD27, which is irreversibly lost with prolonged expo-
sure to antigen (26, 33), and CD57, a marker of terminal dif-
ferentiation (34). Specifi   c functional responses were also 
analyzed with respect to T cell clonotype composition. The 
results provide a detailed picture of CMV-specifi  c CD4+ ef-
fector T cells and indicate a potential role for these cells in the 
control of CMV replication.
RESULTS
Measurement of functional responses to specifi  c 
peptide epitopes
PBMCs from 34 CMV-seropositive healthy volunteers par-
ticipating in the NIH research apheresis program were 
screened with fi  ve previously described CMV epitopes. Indi-
viduals with a frequency of IFN-γ peptide–specifi  c CD4+ T 
cells of 0.2% or greater were studied further. Eight diff  erent 
CMV epitope-specifi  c  CD4+ T responses were found in 
seven subjects (Table I). Peptide-specifi  c CD4+ T cell re-
sponses were polyfunctional. Stimulation with cognate epit-
opes resulted in the production of IFN-γ, TNF-α, and 
MIP-1β, as well as surface mobilization of CD107a (Fig. 1, A 
and B). In addition, IL-2 production was detected in seven of 
the eight responses. The functional hierarchy was dominated 
by production of IFN-γ and TNF-α, followed by MIP-1β 
and surface mobilization of CD107a. IL-2 production was 
the least common functional outcome (Fig. 1 B). In all con-
trol stimulations, backgrounds for each individual function 
were minimal (Fig. 1 A).
Comparison of these responses between diff  erent indi-
viduals required normalization of the data (Table II). The to-
tal frequency of responding CD4+ T cells was set to 100%, 
and the contribution of each functional subgroup was ex-
pressed as a percentage of the total response (Fig. 1 C). Nota-
bly, cells that mobilized CD107a and produced IFN-γ, 
MIP-1β, and TNF-α were most frequent (mean 22 ± 14% 
of the total response). The next most frequent functional sub-
group showed no evidence of surface mobilization of 
CD107a, but it produced IFN-γ, MIP-1β, and TNF-α 
(mean 20 ± 11% of the total response). Cells that produced 
IFN-γ and TNF-α only (mean 15 ± 6% of the total re-
sponse) or IFN-γ alone (mean 12 ± 8% of the total response) 
were still prominent. Almost all responding cells produced 
IFN-γ and TNF-α. Interestingly, cells that produced IL-2 
alone (2 ± 4% of the total response) were rare.
Maturational phenotype of responding CD4+ T cells
We further characterized the CMV-specifi  c CD4+ T cells 
by including maturational markers, allowing simultaneous 
measurement of function and maturational phenotype 
(Table II). Prolonged stimulation of CD27+CD45RO+ 
memory CD4+ T cells has been shown to result in the ir-
reversible loss of CD27 expression in vitro (35). Other 
studies with multiple viral pathogens have suggested that 
loss of CD27 in vivo is accompanied by changes in CD4+ 
Table I.  Age and sex of CMV-seropositive subjects and total frequency of response to peptide epitopes
Subject Age (Sex) Peptide (Class II restriction) Location Total response
1 64 (M) Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A   (DR52) pp65281–295 0.88%
2 55 (F) L  L  Q  T  G  I  H  V  R  V  S  Q  P  S  L   (DR15) pp6541–55 0.64%
3 58 (F) L  L  Q  T  G  I  H  V  R  V  S  Q  P  S  L   (DR15) pp6541–55 0.28%
4 44 (M) P  P  W  Q  A  G  I  L  A  R  N  L  V  P  M  V   (DR11) pp65485–500 0.2%
I  I  K  P  G  K  I  S  H  I  M  L  D  V  A   (DR53) pp65281–295 0.2%
5 23 (M) P  Q  Y  S  E  H  P  T  F  T  S  Q  Y  R  I  Q   (DR11) pp65361–376 0.2%
6 37 (M) P  Q  Y  S  E  H  P  T  F  T  S  Q  Y  R  I  Q   (DR11) pp65361–376 0.2%
7 61 (M) Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A   (DR52) pp65281–295 0.39%
Total response represents the sum of all CD4+ T cells showing surface mobilization of CD107, or production of IFN-γ, IL-2, MIP-1β, or TNF-α in response to stimulation with 
the peptide indicated.
Table II.  Total CD4+ T cell response and percentage of the total response found in the naive, CD27+ memory, CD27− memory, 
CD27−CD45RO−, and terminally differentiated effector CD4+ T cell compartments
Percentage total response mean ± SD Total cells mean ± SD
Naive (CD27+/CD45RO−)1   ± 1 23 ± 18
CD27+ memory (CD27+/CD45RO+) 15 ± 10 42 ± 10
CD27− memory (CD27−/CD45RO+) 77 ± 10 25 ± 12
CD27−/CD45RO− 1 ± 24  ± 3
Terminally differentiated effector cells (CD57+/CD27−/CD45RO+) 28 ± 18 16 ± 12
Values are given as mean ± SD.2868  CD4+ T CELL FUNCTION IN CHRONIC CMV INFECTION | Casazza et al.
T cell function (30, 36–39). For the purposes of this study, 
we classifi  ed cells as naive (CD45RO−CD27+), CD27+ 
memory cells (CD45RO+CD27+), or CD27− memory 
(CD45RO+CD27−). In addition, surface expression of 
CD57 was used as a marker of terminally diff  erentiated ef-
fector cells (34).
In our cohort, naive, CD27+ memory, CD27− memory, 
and CD27− CD45RO− cells accounted for 23 ± 18%, 42 ± 
11%, 25 ± 12%, and 4 ± 3% of the peripheral blood CD4+ 
T cell pool, respectively (values expressed as mean ± SD; 
Table II). The vast majority of the CD4+ peptide–specifi  c T 
cell responses were contained within the CD27− memory 
(77 ± 10%) and CD27+ memory (15 ± 10%) subsets (Table II). 
In addition, a substantial but widely variable percentage of 
the responding CD4+ T cells were terminally diff  erentiated 
eff  ector cells (28 ± 18%).
To explore the relationship between functional response 
and maturational phenotype in more detail, we mapped indi-
vidual functional species to their respective phenotype. This 
is represented visually by mapping individual response pro-
fi   les (Fig. 2 A) onto density plots showing CD27 versus 
CD57 expression (Fig. 2 B), a format that provides optimal 
resolution given that  95% of responding cells on average 
were CD45RO+. Inspection of these plots shows that MIP-
1β–producing CD4+ cells are found at a greater frequency in 
terminally diff  erentiated CD57+ CD4+ T cells than non– 
MIP-1β antigen-specifi  c cells. This is most pronounced in 
IFN-γ–, MIP-1β–, and TNF-α–producing cells that also 
mobilize CD107a. Comparison of IFN-γ–, MIP-1β–, and 
TNF-α–producing cells also show that these cells have a 
higher frequency of CD57 positivity than cells that produce 
IFN-γ and TNF-α alone. Indeed, we found that antigen-
specifi  c CD4+ T cells that produced MIP-1β contained a 
signifi   cantly higher proportion of terminally diff  erentiated 
cells compared with cells that lacked production of MIP-1β 
but were otherwise functionally identical (P < 0.05; not de-
picted). To describe further the relationship between func-
tion and maturational phenotype, we compared the frequency 
of each response in the diff  erent phenotypic subsets (Fig. 2 C). 
Memory CD4+ T cells that were CD27− were more likely 
than memory CD4+ T cells that were CD27+ to mobilize 
CD107a (P ≤ 0.05) and produce MIP-1β (P ≤ 0.01) and 
TNF-α (P ≤ 0.05). IL-2 was produced by a greater propor-
tion of responding CD27+ memory CD4+ T cells than 
CD27− memory CD4+ T cells (P ≤ 0.05). MIP-1β produc-
tion was the only function found to diff  er between terminally 
and nonterminally diff  erentiated eff  ector CD4+ T cells; it 
was increased in terminally diff  erentiated cells (P ≤ 0.05).
To study further the relationship between maturation and 
cytolytic function, we measured the presence of granzyme A, 
granzyme B, and perforin in CD27+ memory cells as well as 
in terminally and nonterminally diff  erentiated CD27− mem-
ory CD4+ T cells in our cohort. Granzyme A was found fre-
quently in CD27+ memory CD4+ T cells (13 ± 5%), but 
granzyme B and perforin were not (2 ± 1 and 1 ± 2%, re-
spectively). These cytotoxic proteins were more commonly 
detected in CD27− memory CD4+ T cells (Fig. 3). The fre-
quency of granzyme A (95 ± 5%), granzyme B (78 ± 15%), 
and perforin (53 ± 33%) in terminally diff  erentiated CD27− 
CD4+ T cells was markedly higher than the frequency of 
granzyme A (41 ± 15%), granzyme B (14 ± 9%), and perforin 
Figure 2.  Mapping functional CMV-specifi  c CD4+ T cell responses 
to maturational phenotype. (A) Individual responses for subject 1. The 
31 possible response profi  les are shown on the x axis, and the total fre-
quency of each response profi  le is shown on the y axis. The dominant 
response profi  les are color coded. (B) The maturational phenotypes of the 
CD4+ T cells expressing each of the dominant response profi  les shown in 
A are overlaid on CD27 versus CD57 plots in which the phenotype of the 
total CD4+ T cell population is shown in gray. Responding cells are repre-
sented as 10% probability contour plots. (C) Functional responses for 
subject 1 (□), subject 2 (■), subject 3 (◇), subject 4 with peptide P  P  W  Q  A-
G I L A R N L V P M V   (○),  subject  4  with  peptide  I I K P G K I S H I M L D V A   (△), subject 
5 (▲), subject 6 (●), and subject 7 (◆) are shown with medians repre-
sented by a horizontal bar. To facilitate comparison between different 
CD4+ T cell subsets (CD45RO+CD27+ and CD45RO−CD27−; and 
CD45RO+CD27−CD57− and CD45RO+CD27−CD57+), data were norma-
lized based on the total frequency of responding cells within each 
maturational subset.JEM VOL. 203, December 25, 2006  2869
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(8 ± 9%) in nonterminally diff  erentiated CD27− CD4+ T 
cells (P < 0.01%). Furthermore, in two subjects, the fre-
quency of terminally diff  erentiated CD27− memory CD4+ T 
cells containing granzyme A, granzyme B, and perforin was 
near 80%.
Surface mobilization of CD107a by CD4+ T cells 
is associated with loss of cytolytic granules
The high frequency of CD4+ T cells showing surface mobi-
lization of CD107a was unexpected because surface mobili-
zation of CD107a by CD8+ T cells identifi  es cells that can 
release cytolytic granules (32, 40, 41), a function not often 
associated with CD4+ T cells. For subject 1, one third of the 
response to the epitope Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A   was con-
tained within the TCRVβ12 subset. This response accounted 
for 16% of the total TCRVβ12 subset. This allowed us to 
determine if loss of granzyme A occurred concurrently with 
surface mobilization of CD107a. After incubation of PBMCs 
with 2 μg/ml of peptide Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A   for 5 h, a 
population of CD107a+ granzyme A–low CD4+ T cells 
emerged. Cells with the brightest CD107a-associated fl  uo-
rescence had the lowest granzyme A content (Fig. 4 A). Sim-
ilar results were seen with granzyme B (Fig. 4 B). Concurrent 
with surface expression of CD107a, the population of CD4+ 
T cells that were CD107− and did not contain granzyme A 
or granzyme B increased by 11 and 9%, respectively, com-
pared with CD4+ T cells from the same individual incubated 
without peptide. Unlike granzyme A, perforin was only pres-
ent in 9% of CD4+ T cells from subject 1 and was almost un-
detectable in TCRVβ12+ CD4+ T cells. These data suggest 
that CD107a expression occurs concurrently with loss of 
granzyme A and granzyme B. These data also suggest that 
granzyme A and granzyme B are lost in these incubations 
without expression of CD107a. Whether this indicates that 
surface expression of CD107a does not identify all cells that 
degranulate, or if another mechanism is responsible for the 
loss of granzyme A and B in these cells, is not clear.
We next demonstrated that the CMV-specifi  c CD4+ T 
cells were capable of specifi  c target cell lysis ex vivo using 
PBMCs from subject 7. In this subject, 50% of the CD4+ T 
cells responding to the peptide epitope Q  E  F  F  W  D  A  N  I  Y  R  I-
F  A   showed evidence of surface mobilization of CD107a. 
65% of the degranulating CD4+ T cells mapped to the termi-
nally diff  erentiated eff  ector subset, and 85% of CD57+ CD4+ 
T cells contained perforin (Fig. 5, A and B). Autologous 
B-LCLs from subject 7 were stained with either CFSE or 
chloromethyl-benzoyl-aminotetramethyl-rhodamine (CMTMR). 
CFSE-stained B-LCLs were loaded with the target peptide 
Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A  , whereas CMTMR-stained B-LCLs 
were not loaded with peptide. PBMCs were added to an equal 
mixture of peptide-loaded CFSE- and CMTMR-stained 
B-LCLs that were not loaded with peptide. The percentage 
of CFSE- and CMTMR-stained B-LCLs was determined 
upon the mixing of B-LCLs with PBMCs and at 8, 16, and 
24 h after mixing. Loss of antigen-loaded B-LCLs increased 
linearly with the number of PBMCs added (Fig. 5 C). Deple-
tion of CD4+ T cells from PBMCs before the incubation of 
PBMCs with B-LCLs resulted in almost no loss of antigen-
loaded B-LCLs during 24 h of incubation. The addition of 
1E06 CD4+ T cells/ml, isolated by elutriation and then puri-
fi  ed by positive selection on a MACS column to B-LCLs, re-
sulted in a threefold increase in the rate of the killing of 
B-LCLs loaded with the peptide Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A   
Figure 3.  Frequency of granzyme A, granzyme B, and perforin in 
CD57− and CD57+ CD27− memory CD4+ T cells. The frequency of 
granzyme A, granzyme B, and perforin in CD57− and CD57+ CD27− mem-
ory CD4+ T cells is shown using box plots, with individual data values 
superimposed for subject 1 (□), subject 2 (■), subject 3 (◇), subject 4 
(○), subject 5 (▲), subject 6 (●), and subject 7 (◆).
Figure 4.  Degranulation of epitope-specifi  c CD4+ T cells. 
(A) Concurrent loss of granzyme A with surface mobilization of CD107a 
in  response  to  peptide  Q E F F W D A N D I Y R I F A   during  a  5-h  incubation  (right) 
compared with the αCD28/49d control stimulation in the absence of 
peptide (left) from TCRVβ12+ CD4+ T cells from subject 1. (B) Concurrent 
loss of granzyme B with surface mobilization of CD107a in response to 
peptide  Q E F F W D A N D I Y R I F A   during  a  5-h  incubation  (right)  compared 
with the αCD28/49d control stimulation in the absence of peptide (left) 
from TCRVβ12+ CD4+ T cells from subject 1.2870  CD4+ T CELL FUNCTION IN CHRONIC CMV INFECTION | Casazza et al.
compared with that observed when 3E06 PBMCs/ml were 
incubated with antigen-loaded B-LCLs (Fig. 5 D). Parallel 
incubation in which 1E06 CD4+ T cells/ml were added to 
30,000 unstained B-LCLs/ml loaded with the peptide Q  E  F  F-
W  D  A  N  D  I  Y  R  I  F  A   resulted in production of IFN-γ of 0.2% 
of CD4+ T cells (Fig. 5 E). This response was entirely within 
the CD4+ T cell subset. Incubation of PBMCs with 30,000 
B-LCLs that had not been loaded with peptide resulted in 
IFN-γ production by 0.03% of CD4+ T cells. Incubation 
of B-LCLs loaded with the P  P  W  Q  A  G  I  L  A  R  N  L  V  P  M  V  , to 
which no response was detected, did not result in B-LCL 
killing. Similar rates of killing were observed whether 
  peptide-loaded B-LCLs were stained with CMTMR or CFSE 
(not depicted). No CD8+ T cell response to the peptide 
Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A   was present in subject 7.
To ensure that the CD4+ T cell killing shown with sub-
ject 7 was not an anomaly, we screened PBMCs from 10 
HIV-infected individuals coinfected with CMV for their re-
sponses to overlapping pp65 peptides. None of these subjects 
had evidence of CMV end organ disease. We identifi  ed two 
individuals in whom the majority of the CD4+ T cells that 
mobilized CD107a in response to stimulation with pp65 
were highly associated with CD57 positivity. Peptide epit-
opes were identifi  ed using pp65 matrices constructed from 
138 15 mers overlapping by 11 (42). The responses of these 
CD4+ pp65-specifi  c T cells were studied further. The fi  rst 
subject was a 53-yr-old male with a CD4 count of 656 and a 
viral load of 553 copies/ml who had not taken antiretroviral 
drugs for >4 yr. In this individual, 0.45% of the CD4+ T cell 
population responded to pp65489–503, A  G  I  L  A  R  N  L  V  P  M  V  A  T  V  . 
Figure 5.  Killing of antigen-loaded autologous B-LCLs by epitope-
specifi  c CD4+ T cells. (A) Mapping of CD4+ T cells from subject 7 that 
degranulate  in  response  to  peptide  Q E F F W D A N D I Y R I F A   (red  dots)  to  the 
CD45RO+CD27− CD4+ T cell compartment and the CD57+ compartment. 
(B) Mapping of perforin to the CD27−CD45RO+ and CD27−CD45RO− 
compartment and the CD57+ compartments. (C) Loss of antigen-loaded 
B-LCLs during incubation with PBMCs. Killing of B-LCLs was determined 
by loss of antigen-loaded, dye-stained B-LCLs as a percentage of the total 
amount of CFSE-stained antigen-loaded and CMTMR-stained unloaded 
B-LCLs in incubations containing none (●) and 1E06 PBMCs (■), 2E06 
PBMCs (◆), and 4E06 PBMCs/ml (▲). Lines are the least square fi  ts of the 
data forced to intersect the y axis at the average of the initial percentage 
of CFSE-stained B-LCLs for all four incubations. Rate of decrease per mil-
lion PBMCs is shown in the inset. (D) Killing of peptide-loaded B-LCLs in 
incubations containing none (●), 3E06 PBMCs after the depletion of 
CD4+ T cells (■), 3E06 PBMCs (▲), and 1E06 CD4+ enriched PBMCs (◆). 
CD4-depleted PBMC CD4+ T cells contained >15× less CD4+ T cells 
compared with CD8+ T cells than nondepleted PBMCs. CD4+-enriched 
PBMC CD4+ T cells represented >99% of CD3+ cells. Both PBMCs and 
B-LCLs are from subject 7. Lines are the least square fi  ts of the data 
forced to intersect the y axis at the average of the initial percentage of 
CFSE-stained B-LCLs for all four incubations. (E) Production of IFN-γ by 
CD4+-enriched T cells after a 6-h incubation with 30,000 B-LCLs either 
without  peptide  or  loaded  with  peptide  Q E F F W D A N D I Y R I F A .  IFN-γ–
 producing  CD3+ T cells are overlaid on a histograph showing CD4+ and 
CD8+ T cells. These assays were performed without costimulation and run 
in parallel with the killing experiments shown in C.JEM VOL. 203, December 25, 2006  2871
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Two diff  erent assays performed on two diff  erent days with 
diff  erent cell preparations showed CD4+ T cells killing. In 
one assay that contained 1.6 E06 CD4+ T cells and 30,000 
peptide-loaded autologous B-LCLs, peptide-loaded B-LCLs 
were decreased by 13%. In the second incubation that con-
tained 1.0 E06 PBMCs and 30,000 autologous peptide-
loaded B-LCLs, peptide-loaded B-LCLs decreased by 11%. 
The second HIV-infected subject was a 43 yr old on antiret-
roviral therapy with a CD4+ T cell count of 612 and a viral 
load of <50 copies/ml. In this individual, 0.34% of the CD4+ 
T cell population responded to the peptide pp65505–520, G  Q-
N  L  K  Y  Q  E  F  F  W  D  A  N  D  . In this individual, killing assays were 
performed three times with three diff  erent cell preparations 
on three diff  erent days. Two incubations contained 2.0E06 
CD4+ T cells per 30,000 peptide-loaded autolgous B-LCLs, 
and one incubation contained 1E06 CD4+ T cells per 30,000 
peptide-loaded autolgous B-LCLs. In the two incubations 
containing 2E06 CD4+ T cells per 30,000 autologous pep-
tide-loaded B-LCLs, decreases in peptide-loaded B-LCLs of 
13.2 and 5.2% were observed during a 24-h incubation. In 
the incubation containing 1E06 CD4+ T cells/ml, an 8.8% 
decrease in antigen-loaded B-LCLs was observed.
We also tried to show expression of CD95L by peptide-
specifi  c CD4+ T cells in subject 7. Although we were able to 
see CD95L expression with staphylococcal enterotoxin B 
stimulation, we could not see evidence of surface mobili-
zation CD95L in response to stimulation with the peptide 
Q  E  F  F  W  D  A  N  D  I  Y  R  I  F  A  .
Comparison of functional response profi  les in different 
viral infections
Virus-specifi  c CD4+ T cell responses have been reported to 
exhibit diff  erent functional responses in diff  erent infections 
(30, 38, 39, 43, 44). We therefore conducted similar func-
tional profi  ling studies of responding CD4+ T cells in HIV-
infected long-term nonprogressors and individuals infected 
with vaccinia virus during a smallpox vaccine trial (Fig. 6). 
Multifunctional responses, including the production of MIP-
1β and surface expression of CD107a, were substantially 
more frequent in CD4+ T cell populations specifi  c for CMV 
pp65 than in those specifi  c for either HIV-1 Gag in long-
term nonprogressors or vaccinia virus in vaccine recipients.
Clonotype analysis of degranulating CD4+ T cells
We next asked whether terminally diff  erentiated degranulat-
ing CD4+ T cells represent a clonally restricted subset of the 
total CD4+ T cell response to a given epitope. To accom-
plish this, we needed to sort live, unpermeabilized CD4+ T 
cells that did and did not degranulate (45). Although not rou-
tinely used in this study, surface mobilization of CD154 
identifi  es almost all activated CD4+ T cells (46). Our data 
support these fi  ndings in CMV-specifi  c CD4+ T cells. Using 
CMV-derived peptides, we found that surface expression of 
CD154 in our cohort occurred concomitantly with IFN-γ 
production (not depicted) and was limited almost exclusively 
to the CD27+ and CD27− memory CD4+ T cell pools. 
Therefore, by using surface mobilization of CD154 and 
CD107a, we were able to sort responding CD4+ T cells into 
degranulating and nondegranulating populations suitable for 
clonotypic analysis.
After stimulation with cognate peptide, CD107a+CD154+ 
(degranulating) and CD107a−CD154+ (nondegranulating) 
CD4+ T cells were sorted and subjected to clonotype analysis 
(Fig. 7). In each case, the sorted CD4+ T cell population was 
oligoclonal; the three dominant CD107a+CD154+ clono-
types accounted for the majority of the degranulating popula-
tion (subject 7, 61%; subject 1, 82%; subject 2, 81%). Although 
the clonotypes sequenced for the degranulating and nonde-
granulating responses were similar, the frequency of clono-
types was diff  erent in these subsets. Clonotypes that were 
represented more frequently within the degranulating CD4+ 
T cell population occurred less frequently in the nondegran-
ulating subset. The frequency of clonotypes determined by 
molecular analysis was substantiated by fl  ow cytometric stud-
ies with TCRVβ mAbs in two subjects (1 and 7), thereby 
validating the quantitative nature of the RT-PCR method in 
this setting (not depicted). In sum, these data are consistent 
Figure 6.  Functional response patterns for CD4+ T cells with 
different viral specifi  cities. PBMCs from (A) subjects with chronic CMV 
stimulated with overlapping pp65 peptides (n = 5); (B) HIV-infected long-
term nonprogressors stimulated with overlapping Gag peptides (n = 11); 
and (C) smallpox vaccinees stimulated with whole vaccinia virus 1 mo 
after vaccination (n = 6). In each panel, the 31 possible response profi  les 
are shown on the x axis, and the percentage of the total response is 
shown on the y axis. The mean percentage of the total CD4+ response for 
each of 31 functional species is shown ± SD.2872  CD4+ T CELL FUNCTION IN CHRONIC CMV INFECTION | Casazza et al.
with the acquisition of lytic function by terminally diff  erenti-
ated eff  ector memory phenotypes that are unrelated to clo-
notypic composition.
DISCUSSION
The role of CD4+ T cells in B cell maturation, immunoglo-
bin class-switching, and licensing of antigen-presenting cells 
to promote the expansion of functional CD8+ cytotoxic T 
lymphocytes is well established. Less is known about the role 
of CD4+ T cells in the direct control of infection. Here, we 
demonstrate that highly diff  erentiated CD4+ T cells, specifi  c 
for CMV pp65, mediate antiviral eff  ector functions. Specifi  -
cally, we fi  nd that: (a) CD27− memory CD4+ T cells can 
degranulate in response to cognate antigen; (b) a greater pro-
portion of CD4+ T cells contains granzyme A, granzyme B, 
and perforin as they mature; (c) CD4+ T cells from an indi-
vidual in which degranulation occurred in a subset of cells 
with a high frequency of perforin killed target cells bearing 
the cognate CMV pp65-derived MHC class II–restricted ep-
itope; and (d) the frequency of CD4+ T cells that degranulate 
and produce MIP-1β increases with maturational status. In 
addition, we sorted activated CD4+ T cells into degranulat-
ing and nondegranulating populations and showed that de-
granulating CD4+ T cells were not clonotypically unique.
Although our data show epitope-specifi  c killing of B-
LCLs by CD4+ T cells from subject 7, the subject in whom 
the majority of the surface mobilization of CD107a occurred 
in a population of CD4+ T cells with a high frequency of 
perforin expression, our data do not show a direct link be-
tween surface mobilization of CD107a, perforin, and gran-
zyme content and killing. In fact, it is possible that 
perforin-independent pathways may be involved in CD4+ T 
cell killing that we have shown in three individuals. Although 
we looked for other pathways and could not provide evi-
dence that they were operative, it is still possible that the ex-
pression of FAS ligand was below our ability to detect, or a 
TNF-α–dependent mechanism was responsible for the ob-
served killing.
Although we cannot say with certainty what the mecha-
nism of CMV antigen-specifi  c killing is, we have shown 
Figure 7.  Clonotypic composition of peptide-responsive 
CD4+CD107a+CD154+ and CD4+CD154+ T cell populations. Func-
tional responses to cognate antigen stimulation and sort gates are shown 
in the left panels for subject 7 (A), subject 1 (B), and subject 2 (C). The 
corresponding TCRBV usage, CDR3 amino acid sequence, and TCRBJ usage 
of the depicted CD4+ T cell populations are shown in the right panels 
with the percentage frequency of each clonotype and the total number of 
clones sequenced.JEM VOL. 203, December 25, 2006  2873
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ample evidence of ex vivo killing. We have shown killing 
with three diff  erent individuals using three diff  erent peptide 
epitopes. In each case killing was shown with repeated assays. 
In subject 7, we demonstrated killing twice with purifi  ed 
CD4+ T cells and fi  ve diff  erent times with concentrations of 
PBMCs ranging from 1 to 4E06/ml. In the two individuals 
infected with HIV, CMV epitope-specifi  c killing was shown 
in two and three diff  erent assays, respectively. In all of our as-
says, the ratio of peptide-loaded B-LCLs to nonloaded B-
LCLs was determined at either three or four diff  erent time 
points. In addition, to assure that the observed killing was not 
artifactual, we loaded autologous B-LCLs with an irrelevant 
peptide and failed to show killing using PBMCs from subject 
7. In almost all cases, and at least once for each person in 
which killing was demonstrated, we ran parallel control incu-
bations using the same antigen-loaded and -unloaded stained 
autologous B-LCLs that were used in the killing assays. In 
these assays no eff  ector cells were added. This assured that 
there was not a signifi  cant diff  erence in the rate of growth 
between B-LCLs caused by either the peptide used or by 
staining with CMTMR or CSFE. In all of the above-men-
tioned incubations, when incubations were performed under 
the appropriate circumstances, killing was observed. We did 
not observe killing in all cases. We tried to show killing using 
cells from subjects 1 and 6. In subject 1, using 1E06 CD4+ T 
cells prepared by either positive or negative selection, we 
failed to show killing in two diff  erent assays. In subject 6, us-
ing either 1E06 PBMCs or 1E06 CD4+ T cells prepared by 
negative selection, we also failed to see any evidence of kill-
ing in two diff  erent assays.
Several reports have tried to describe functional capacity 
using changes in the expression of surface markers (26, 39, 
47, 48). These reports have used a combination of reversible 
and irreversible surface markers. Many of these markers have 
well-established functional roles themselves. We followed 
three easily measured surface markers: CD45RO, the iso-
form of CD45 associated with the transition from naive to 
memory cell, CD27, a costimulatory marker irreversibly lost 
with exposure to cognate epitope, and CD57, a marker of 
replicative incompetence. As others have suggested, our data 
show frequent production of IFN-γ, and TNF-α, and de-
creased IL-2 frequencies as CD4+ T cells mature (49, 50). 
Similarly we fi  nd that CD4+ T cells show an increased fre-
quency of degranulation and MIP-1β production with matu-
ration. Nonetheless, ascribing all functionality to maturation 
appears to be an over simplifi  cation. The amount of perforin 
present in CD4+ T cells varies greatly in CD57+ T cells. 
Similarly, it seems clear from the data presented in Fig. 6 that 
degranulation occurs at diff  erent frequencies in response to 
diff  erent pathogens, even with similar levels of expression 
of CD27 and CD57. Whether these diff  erences are due to 
diff  erent milieus at initial encounter of cognate epitope, or 
to changes that occur during chronic stimulation, remains to 
be determined.
The delay in the development of cytotoxic function and 
MIP-1β production to the stage at which CD4+ T cells ac-
quire an eff  ector phenotype is attractive teleologically. Such 
a delay in the development of these functions would serve to 
protect MHC class II–presenting cells in lymphoid tissue 
from damage during periods when CD4+ T cell help is re-
quired to develop and maintain an eff   ective immune re-
sponse. At the same time, eff  ector CD4+ T cells could 
contribute to the control of pathogens in peripheral tissues. 
Indeed, in many ways the functional progression that we 
demonstrate here during CMV-specifi  c CD4+ T cell diff  er-
entiation is similar to that seen in CD8+ CTL development 
(37), even though eff  ector CD4+ T cells in the periphery 
should still be able to supply help through the CD154–CD40 
pathway. The persistent expression of CD154/40L, even in 
cells that are CD57+, suggests the importance of this ligand in 
CD4+ T cell function. Although much speculation is possi-
ble, we can certainly conclude that the pattern of response 
described here is more complicated than has been previously 
suggested for most virus-specifi  c CD4+ T cells (51, 52).
The clonotypic data indicate a more varied CD4+ clonal 
response to CMV than suggested previously by others (53). 
Rather than one dominant clonotype, we see a more bal-
anced response with at least three or four prevalent clono-
types in each epitope-specifi  c CD4+ T cell population. There 
are several possible reasons for this diff  erence in the apparent 
number of antigen-responsive clones. First, sorting antigen-
responsive CD4+ T cells by CD107a and CD154 readouts 
may identify lower frequency clones than previously 
reported. It is also possible that the selection of subjects 
with a high response frequency to a specifi  c epitope could 
select for more polyclonal MHC class II–restricted CD4+ T 
cell populations.
Overall, our data indicate that as pp65-specifi  c CD4+ T 
cell clonotypes progress from CD27+ memory to a termi-
nally diff  erentiated eff  ector memory phenotype, they acquire 
greater eff   ector, and specifi   cally cytotoxic, potential. The 
role of these CD4+ T cells in providing help is unclear. The 
relatively low frequency of IL-2–producing CD4+ T cells 
compared with IFN-γ, TNF-α, and MIP-1β production 
suggests that the primary role of CMV pp65-specifi  c CD4+ 
T cells during chronic infection is not one of supplying CD4+ 
T cell help. The role of the CD40L–CD95 pathway in these 
cells remains unclear. Our fi  ndings do not apply to all CD4+ 
T cells specifi  c to every virus (Fig. 6) and may not necessarily 
apply to other CMV proteins. However, our data support a 
model where certain unique antiviral eff  ector functions of 
virus-specifi  c CD4+ T cells are elaborated after an appropri-
ate maturational state has been achieved. It remains to be de-
termined whether the expression of these functions is 
dependent on key characteristics of the pathogen to which 
the CD4+ T cells are targeted, or the immunologic milieu in 
which those T cells become initially or subsequently stimu-
lated during the course of the infection.
MATERIALS AND METHODS
Subjects. PBMCs were obtained from CMV-seropositive healthy volun-
teers participating in the NIH research apheresis program (Table I) and from 2874  CD4+ T CELL FUNCTION IN CHRONIC CMV INFECTION | Casazza et al.
healthy HIV-infected volunteers participating in the vaccine research centers 
(VRC) apheresis protocol or by venapucture from HIV-infected volunteers 
participating in the VRC positive and negative protocol. When elutriated 
lymphocytes were prepared, mononuclear cells prepared by apheresis were 
further purifi  ed by elutriation using a Gambro Elutra. Lymphocytes prepared 
in this manner were routinely >85% lymphocytes. Signed informed consent 
approved by the NIH Institutional Review Board was obtained in each case. 
PBMCs were obtained by standard Ficoll-Hypaque (GE Healthcare) density 
gradient centrifugation and cryopreserved in FCS (Invitrogen) containing 
10% DMSO (Fisher Scientifi   c) using a Cryomed Freezer (model 7454; 
Thermo Electron Corporation). All PBMC preparations were screened for 
responses to fi  ve previously identifi  ed CMV-specifi  c MHC class II–restricted 
epitopes (54, 55). Subjects with CD4+ T cell responses to a single peptide 
>0.2%, as determined by intracellular production of IFN-γ, were used for 
further study.
Peptides. Peptides representing CMV-derived epitopes (54, 55) were syn-
thesized and purifi  ed by Bio-Synthesis Inc. and were >80% pure by high 
performance chromatography (Table II). 138 15 mers overlapping by 11 
spanning the entire pp65 protein were obtained from JPT Peptide Technol-
ogy and were >70% pure. All peptides were dissolved in DMSO and stored 
at −20°C. The fi  nal concentration of each peptide in PBMC assays was 
2 μg/ml.
Antibodies. Directly conjugated mAbs specifi   c for the molecules listed 
were obtained from the following: IL-2-allophycocyanin (APC), CD3-Cy-
7APC, CD20-APC, CD107a-FITC, CD95-PE, CD154-PE, IFN-γ–FITC, 
MIP-1β–PE, TNF-α–PECy7, perforin-FITC, granzyme A–PE, and gran-
zyme A-FITC from BD Biosciences; CD45RO–Texas red–PE (TRPE) and 
TCRVβ12-PE from Beckman Coulter; and granzyme B-APC and CD4-
PECy5.5 from Caltag. The following antibodies were conjugated in our 
laboratory according to standard protocols (http://drmr.com/abcon/index.
html): CD4–Cascade blue, CD8–quantum dot (QD) 655, CD27–Cascade 
blue, CD14-PECy5, CD19-PECy5, CD57-QD545, and CD107a–Alexa 
680. Unconjugated mAbs were obtained from BD Biosciences, Cascade 
blue and Alexa 680 were obtained from Invitrogen; Cy5 was obtained 
from GE Healthcare, and quantum dots were obtained from Quantum 
Dot Corporation.
Cell stimulation and staining. Cell stimulation and staining were per-
formed using a modifi  cation of the method described by Betts et al. (32). 
Purifi  ed PBMCs were thawed, resuspended at 2 × 106 cells/ml in complete 
RPMI media (RPMI 1640 supplemented with 10% heat-inactivated FCS, 
100 U/ml penicillin G, 100 μg/ml streptomycin sulfate, and 1.7 mM so-
dium glutamamine; R10), and rested for 2 h at 37°C in the presence of 
10 U/ml DNase I (Roche Diagnostics). Cells were then washed with R10 
and readjusted to 2 × 106 cells/ml. Costimulatory antibodies (αCD28 and 
αCD49d; 1 μg/ml fi  nal concentration; Becton Dickinson), monensin (0.7 
μg/ml fi  nal concentration; BD Biosciences), brefeldin A (10 μg/ml fi  nal 
concentration; Sigma-Aldrich), αCD107a–Alexa 680 (pretitered volume), 
and in some cases αCD154-PE (pretitered volume) were added to cells, 
which were then transferred in 1-ml aliquots to polystyrene tubes containing 
5 μl of each peptide or peptide mix. A negative control containing PBMCs 
from the same individual but with no added peptide was included for each 
assay. Cells were incubated for 5.5 h at 37°C. For Vaccinia virus–specifi  c re-
sponses, 2 × 106 PBMCs were infected with Vaccinia virus (multiplicity of 
infection = 1) in 200 μl R10 for 1 h at 37°C. R10 was then added to adjust 
the total volume to 1 ml, and the cells were incubated for an additional 3 h 
before the addition of brefeldin A, monensin, and αCD107a–Alexa 680. 
Cells were then mixed and incubated at 37°C for an additional 5 h. Negative 
control tubes, without the addition of vaccinia virus, were included for all 
samples. After incubation, cells were washed once with PBS containing 1% 
bovine serum albumin and 0.1% sodium azide, and surface stained with the 
appropriate directly conjugated antibodies for 20 min in the dark at 4°C. The 
cells were then washed again and permeabilized using the cytofi  x/cytoperm 
kit (BD Biosciences) according to the manufacturer’s instructions. After in-
tracellular staining for CD3, CD4, IFN-γ, MIP-1β, IL-2, and TNF-α, the 
cells were washed one fi  nal time and fi  xed in PBS containing 1% paraformal-
dehyde. Fixed cells were stored at 4°C until the time of collection.
Maximal responses were obtained between 5 1/2 and 8 h. During this 
time, no change in the ratio of responses was observed with the increases 
in all functions being proportional to each other. Although total CD107a 
responses continued to increase between 5 1/2 and 8 h, mean fl  orescence 
started to decrease during this time. To maximize the accuracy of CD107a 
gating, an incubation time of 5 1/2 h was used for all multicolor 
fl  ow experiments.
In incubations in which cells were purifi  ed by either positive or nega-
tive selection, purifi  cation was performed using MACS methodology as rec-
ommended by the manufacturer (Miltenyi Biotec). CD4+ T cells purifi  ed by 
positive selection were >99.5% pure based on total CD3+ expression. In all 
cases, cells were allowed to rest for at least 2 h before assay.
Flow cytometric analysis. Cells were analyzed with either a modifi  ed 
fl  ow cytometer (LSRII; BD Immunocytometry Systems) equipped for the 
detection of 17 fl  uorescent parameters, or with a FACSCalibur (BD Immuno-
cytometry). For four-color fl  ow cytometry, between 100,000 and 250,000 
events were collected from each sample, and for polychromatic fl  ow cytom-
etry, between 500,000 and 1,000,000 total events were collected from each 
sample. Electronic compensation was conducted with antibody capture 
beads (BD Biosciences) stained separately with individual mAbs used in the 
test samples. Data analysis was performed using FlowJo version 6.0 (TreeS-
tar). For polychromatic analysis, initial gating of each sample set used a for-
ward scatter area versus a forward scatter height plot to gate out cell 
aggregates. The cells were then gated through a forward scatter area versus a 
side scatter height plot to isolate small lymphocytes. After this, CD14+ and 
CD19+ cells were removed from the analysis to reduce background staining 
with αCD107a. Finally, cells were gated through a CD3 versus Cascade blue 
plot to remove dead cells (Cascade blue bright staining can be used as a sur-
rogate marker of viability; unpublished data). Data are reported after back-
ground correction using costimulated cells from the same individuals in the 
absence of peptide for comparison. Importantly, nonspecifi  c background be-
comes extremely low when combinations of functions are being examined, 
nearly always reaching zero events when three or more functions are being 
examined simultaneously. The background tends to be higher for single-
positive responses, particularly for CD107a. Cut-off   for a positive responses 
was 10 events.
CD95L staining. CD95 staining was performed using a coculture method 
similar to that used for CD107. PBMCs were incubated with and without 
peptide in R10 containing 10 ng/ml Galardin (Sigma-Aldrich) and costimu-
latory antibodies (αCD28 and αCD49d; 1 μg/ml fi  nal concentration for 5 h, 
and either or both fl  uorescently labeled CD107a and CD95L). Cells were 
washed and surface stained for CD3 and CD4. When IFN-γ was stained, 
cells were permeabilized and stained as described previously (56).
Killing assays. The killing assay used was a modifi  cation of the previously 
published VITAL assay (57, 58). EBV-transformed B-LCLs were prepared 
using standard procedures (59) and cryopreserved until needed. B-LCLs 
were stained with either CFSE (34) or CMTMR (57), as described previ-
ously. Stained cells were then added to either R10 medium or R10 supple-
mented with 2 μg/ml of the peptide epitope of interest. After incubation for 
1 h, cells were counted and washed twice with R10. The B-LCLs were then 
mixed to contain equal numbers of peptide-loaded CFSE-stained B-LCLs 
and unloaded control CMTMR-stained B-LCLs, or equal numbers of pep-
tide-loaded CMTMR-stained B-LCLs and unloaded control CFSE-stained 
B-LCLs. Next, 300,000 of these mixed cells were washed one fi  nal time and 
combined with PBMCs or CD4+ T cells in a total volume of 5 ml. 1-ml ali-
quots were added to 4.5 ml polypropylene tubes. Final concentrations of an-
tigen-loaded B-LCLs and unloaded control B-LCLs were 30,000/ml each in 
all assays. PBMCs and CD4+ T cells concentrations varied as noted in JEM VOL. 203, December 25, 2006  2875
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Results. Tubes were then placed in a 37°C, 5% CO2 incubator. Incubation 
mixtures were processed at 0, 8, 16, and 24 h. For processing, cells were 
washed once in PBS containing 1% bovine serum albumin and 0.1% sodium 
azide, and stained for 30 min with αCD20-APC at 4°C. Cells were then 
washed again, fi  xed with 1% paraformaldehyde, and analyzed using a FACS-
Calibur fl  ow cytometer (BD Immunocytometry).
Cell sorting. PBMCs were prepared and rested as described above, and 
then incubated for 5 h in R10 supplemented with αCD28 and αCD49d 
(each at 1 μg/ml fi  nal concentration), monensin (0.7 μg/ml fi  nal concentra-
tion), αCD107a–Alexa 680 (pretitered volume), αCD154-PE (pretitered 
volume), and 2 μg/ml of peptide in a modifi  cation of the method described 
by Chattopadhyay et al. (46) and Betts et al. (32). Cells were then washed 
once more with R10, and propidium iodide (Sigma-Aldrich) was added to a 
fi  nal concentration of 5 μg/ml as a viability marked immediately before sort-
ing. Cells were sorted at 25 pounds per square inch using a modifi  ed FACS 
DIVA (Becton Dickinson). Instrument set-up was performed according to 
the manufacturer’s instructions. Electronic compensation was conducted 
with antibody capture beads (BD Biosciences) stained separately with the in-
dividual mAbs used in the test samples. Small CD3+, CD4+, CD14−, and 
CD19− lymphocytes that were CD154+/CD107a+ or CD154+/CD107a− 
were collected separately and frozen in RNAlater (Ambion) for clono-
type analysis.
Clonotype analysis. Thawed cells were lysed and subjected to mRNA ex-
traction (Oligotex kit; QIAGEN). A template switch–anchored RT-PCR 
using a 3′ TCRB constant region primer (5′-G  C  T  T  C  T  G  A  T  G  G  C  T  C  A  A  A-
C  A  C  A  G  C  G  A  C  C  T  C  -3′) was then performed as described previously (45, 
60). Amplifi  ed products were ligated into pGEM-T Easy vector (Promega) 
and cloned by transformation of competent DH5α Escherichia coli. Selected 
colonies were amplifi  ed by PCR using standard M13 primers and then se-
quenced from an insert-specifi  c primer using fl   uorescent dye terminator 
chemistry (Applied Biosystems). A minimum of 50 clones was generated and 
analyzed per sample. Pseudogenes and “nonfunctional” sequences that could 
not be resolved after inspection of the individual chromatograms were dis-
carded from the analysis. Nucleotide comparisons were used to establish 
clonal identity. All sequences that were only found once in each cell popula-
tion were disregarded. Data analysis was performed using Sequencher Ver-
sion 4.2 (Gene Codes Corporation). The International Immunogenetics 
nomenclature system is used throughout this work (61).
Statistical analysis. Comparison between groups was performed using a 
criterion of signifi  cance of P ≤ 0.05. All statistical tests were conducted us-
ing SPSS for Windows, and all means are reported ± the SD. Pair-wise 
comparisons were made using a Wilcoxon signed rank statistic.
Online supplemental material. Figs. S1 and S2 show CMV epitope–spe-
cifi  c CD4+ T cell killing assays for two diff  erent individuals, both infected 
with HIV. In addition, the mapping of CD4+ T cells with respect to surface 
expression of CD27, CD45RO, and CD57 is shown for CD4+ T cells that 
surface mobilize CD107a in response to stimulation with cognate epitope. 
Similar fi  gures are shown for perforin containing CD4+ T cells. Figs. S1 and S2 
are available at http://www.jem.org/cgi/content/full/jem.20052246/DC1.
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